Biocon informs about press release

23 Oct 2025 Evaluate
Biocon has informed that it enclosed the press release titled ‘Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara®’. The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.  

Biocon Share Price

375.15 -2.40 (-0.64%)
19-Jan-2026 15:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1672.95
Dr. Reddys Lab 1168.25
Cipla 1386.00
Zydus Lifesciences 879.00
Lupin 2178.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×